Northern Trust Corp Has $7.58 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Northern Trust Corp lifted its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 8.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 284,587 shares of the company’s stock after buying an additional 22,657 shares during the period. Northern Trust Corp’s holdings in Castle Biosciences were worth $7,584,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CSTL. Wellington Management Group LLP acquired a new position in Castle Biosciences in the 4th quarter valued at $19,244,000. Renaissance Technologies LLC grew its stake in Castle Biosciences by 39.9% in the 4th quarter. Renaissance Technologies LLC now owns 685,000 shares of the company’s stock valued at $18,255,000 after buying an additional 195,438 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Castle Biosciences by 15.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 999,466 shares of the company’s stock valued at $26,636,000 after buying an additional 134,645 shares during the last quarter. Vanguard Group Inc. grew its stake in Castle Biosciences by 4.8% in the 4th quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company’s stock valued at $48,837,000 after buying an additional 83,783 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. acquired a new position in Castle Biosciences in the 4th quarter valued at $1,959,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Canaccord Genuity Group reduced their price target on shares of Castle Biosciences from $42.00 to $37.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the company a “buy” rating in a report on Friday, March 28th. Lake Street Capital reduced their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. Finally, Robert W. Baird increased their price target on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $37.50.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $16.75 on Monday. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The firm’s fifty day moving average price is $19.49 and its two-hundred day moving average price is $24.99. Castle Biosciences, Inc. has a 1 year low of $15.70 and a 1 year high of $35.84. The firm has a market capitalization of $483.61 million, a P/E ratio of 83.75 and a beta of 1.19.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.12). Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The company had revenue of $87.99 million during the quarter, compared to analyst estimates of $80.40 million. As a group, research analysts anticipate that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,236 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $21.52, for a total transaction of $26,598.72. Following the sale, the insider now directly owns 74,627 shares in the company, valued at $1,605,973.04. This represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 27,454 shares of company stock worth $553,030. Corporate insiders own 7.20% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.